Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03288324 · ClinicalTrials.gov registry record · Phase 1
Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus
A Phase 1 study of Systemic Lupus Erythematosus and Cutaneous Lupus, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 2
- Study locations
NCT03288324 is a Phase 1 study of Systemic Lupus Erythematosus and Cutaneous Lupus that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 13 participants, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03288324, a Phase 1 study of Systemic Lupus Erythematosus and Cutaneous Lupus, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 2
- Study locations
Study Summary
This 76-week, 3-part Phase 1b/2 study is intended to evaluate the pharmacological properties (pharmacokinetics and pharmacodynamics), safety, tolerability and preliminary effectiveness of TOFA administrated to young adults (18-45 years) with moderately to severely active SLE-CL. Subjects will be studied at the Cincinnati Children's Hospital Medical Center (CCHMC) and in Cleveland at MetroHealth Medical Center.
Conditions Studied
Interventions
- DRUG Tofacitinib
Study Locations (2)
Ohio
- Cincinnati Childrens Hospital Medical Center - Cincinnati
- MetroHealth Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-08-23 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03288324
The ClinicalTrials.gov registry entry for NCT03288324 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (97% lower). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which Tofacitinib is the first listed.
NCT03288324 reports 2 study locations spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT03288324 about?
NCT03288324 is a clinical study titled "Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus". This 76-week, 3-part Phase 1b/2 study is intended to evaluate the pharmacological properties (pharmacokinetics and pharmacodynamics), safety, tolerability and preliminary effectiveness of TOFA administrated to young adults (18-45 years) with moderately to severely active SLE-CL. Subjects will be stu...
What is the current status of trial NCT03288324?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2017-08-23. Estimated completion is 2023-12-01.
What conditions does trial NCT03288324 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus, Cutaneous Lupus.
What interventions are being tested in trial NCT03288324?
The interventions under investigation include: Tofacitinib (DRUG).
Who is sponsoring clinical trial NCT03288324?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03288324 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
REACT-01: Reversing Autoimmunity Through Cell Therapy
RECRUITING · Phase 1
-
Alnuctamab for Refractory SLE (LATTE Study)
RECRUITING · Phase 1
-
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.